ImmuCell reports Q2 2026 results, expands capacity plans

ImmuCell (NASDAQ: ICCC ) released second-quarter financial results and hosted an earnings call on Friday.

Read the complete transcript below.

This content is powered APIs.

For comprehensive financial data and transcripts, visit View the webcast at Summary ImmuCell Corporation reported a 11.5% increase in second-quarter product sales to $7.2 million, with a notable 27.7% growth in domestic sales offset by a 38.9% decline in international sales.

The company focused strategically on the calf scours market with their product First Defense, resulting in accelerated growth and increased market share, particularly in the U.S.

Gross margin fell to 33.9% from 43.7% year-over-year due to lower manufacturing output and a cost shift from the Re-Tain product into cost of goods sold.

Net income for the second quarter was $1.8 million, buoyed by a $2 million settlement from a former contract manufacturer, contributing to a strong balance sheet with $8.9 million in cash.

ImmuCell announced significant capacity expansions with planned investments totaling $8 million, aimed at tripling manufacturing capacity and reducing product costs.

The company is also making progress in international markets and expanding its commercial team to support strategic growth initiatives.

The long-term outlook is positive, with focus on improving yields and securing scalable growth through reliable supply chain management.

Full Transcript OPERATOR Good morning and welcome to the ImmuCell Corp conference call to discuss unaudited second quarter 2026 financial results.

All participants will be in listen-only mode.

Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad.

After today's presentation, there will be an opportunity to ask questions.

To ask a question, you may press star then one on your telephone keypad.

To withdraw your question, please press star then two.

Please note this event is being.

I would now like to turn the conference over to Joe Diaz of Lytham Partners.

Please go ahead.

Joe Diaz, Lytham Partners (Investor Relations) Thank you.

Good morning and welcome.

As the conference call operator indicated, my name is Joe Diaz with Lytham Partners.

We are the investor relations consulting firm for ImmuCell Corp.

I thank all of you for joining us today to discuss the unaudited earnings for the second quarter and six months ended June 30, 2026.

Listeners are reminded and cautioned that statements made by management during the course of this call include forward-looking statements, which include any statement that refers to future events or expected future results or predictions about steps the Company plans to take in the future.

These statements are not guarantees of performance and are subject to risks and uncertainty that could cause actual results, outcomes, or events to differ materially from those discussed today.

Additional information regarding forward-looking statements and the risks and uncertainties that could impact future results, outcomes, or events is available under the Cautionary Note regarding Forward-Looking Statements or the Safe Harbor statement provided with the press release that the Company filed last night, along with the Company's other periodic filings with the SEC.

Information discussed on today's call speaks only as of today, Friday, August 14, 2026.

The Company undertakes no obligation to update any information discussed on today's call.

Please note that references to certain non-GAAP financial measures may be made during today's call.

With that said, let me turn the call over to Oliver te Buchorst, President and CEO of ImmuCell Corp, for some opening remarks.

Oliver.

Oliver te Buchorst, President and CEO Thanks, Joe, and good morning, everyone.

It's my pleasure to welcome you to today's discussion of ImmuCell's results for the second quarter of 2026.

Our discussion of results will be accompanied by a few slides that are also part of our updated investor presentation that you can find on our Investor page, immucell.com/investors.

In late 2025, ImmuCell made significant changes to better position ourselves for success, including a strategic focus on the calf scours market and investments in leadership, sales force expansion, and manufacturing.